NICE rejects arthritis drug in draft advice

Golimumab has not been recommended for use in treating psoriatic arthritis, under draft guidance issued by NICE.

Psoriatic arthritis  (Photograph: SPL)
Psoriatic arthritis (Photograph: SPL)

The drug is licensed for use alone, or in combination with methotrexate, for active and progressive psoriatic arthritis in adult patients when previous therapy has been inadequate.

It is also licensed for limited use in the treatment of rheumatoid arthritis and ankylosing spondylitis.

NICE has made the recommendation because research shows golimumab is not more cost-effective than other available options. A spokesman said: 'NICE recommends adalimumab, etanercept and infliximab for the treatment of psoriatic arthritis in people with peripheral arthritis. The cost-effectiveness analyses found that golimumab was not the most cost-effective of the available options currently recommended by NICE.'

A secondary reason for the advice was uncertainty about possible side-effects of the drug, as a long-term follow-up on adverse outcomes is ongoing.

The spokesman added that economic modelling based on evidence about golimumab had shown the drug may be less cost-effective than etanercept, and 'could not be considered a good use of NHS resources'.

The drug's manufacturer MSD said: 'MSD strongly believes that any restrictions on access to this treatment would inhibit patient choice for the treatment of this disabling and chronic disease.'

The draft guidance is open to consultation.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Practices handed one-month opt-out window as revamped network DES unveiled

Practices handed one-month opt-out window as revamped network DES unveiled

NHS England has unveiled a revamped DES package for 2020/21 confirming new targets,...

GPs delivered huge rise in face-to-face consultations in week before NHS England letter

GPs delivered huge rise in face-to-face consultations in week before NHS England letter

GPs delivered a huge increase in face-to-face appointments in the week before NHS...

RCGP facing legal action over stance on assisted dying

RCGP facing legal action over stance on assisted dying

The RCGP is facing legal action over its decision to remain opposed to assisted dying...

Medeconomics Live aims to help practices thrive under the new GP contract

Medeconomics Live aims to help practices thrive under the new GP contract

The one-day, virtual Medeconomics Live conference aims to provide practices with...

GPs face wave of abuse and complaints after NHS England face-to-face appointments claims

GPs face wave of abuse and complaints after NHS England face-to-face appointments claims

GP practices have faced a wave of abuse and complaints after a letter from NHS England...

Government denies plan to make GPs 'gatekeepers' of COVID-19 testing

Government denies plan to make GPs 'gatekeepers' of COVID-19 testing

The government has denied plans to make GPs 'gatekeepers' of the struggling COVID-19...